Among antidepressants, selective serotonin and noradrenaline reuptake inhibitors (SSRIs and SNRIs) have been widely used in the treatment of major depression and may induce sleep disorders and bruxism. In the present study, the effects of SSRIs and SNRIs on awake and sleep bruxism have been evaluated. A total of 125 patients who had been prescribed SSRIs or SNRIs for the treatment of major depression have been evaluated for bruxism. For the purpose of the study, data from the first week (T1) and the fourth week (T2) of antidepressant treatment have been considered. In conclusion, in the early period, the presence of bruxism has not been observed to be significantly influenced by the use of antidepressants. It has been determined that sleep bruxism increased in the fourth week only in males who were using antidepressants (p = 0.015; p < 0.05). An increase in the presence of sleep bruxism due to specific SSRIs and SNRIs has been determined in the fourth week of drug use. Paroxetine in the SSRI group and duloxetine in the SNRI group have been found to cause an increase in sleep bruxism (p = 0.013; p < 0.05). Other active substances have not been found to affect sleep or awake bruxism significantly. The present study has shown that although some antidepressants increase bruxism in the early period of drug use, the effects of similar drugs on sleep or awake bruxism need to be evaluated in detail in long-term studies.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.24869/psyd.2024.225 | DOI Listing |
Arch Womens Ment Health
December 2024
College of Pharmacy, Jinan University, Guangzhou, Guangdong, China.
Purpose: This study investigates the potential association between commonly prescribed psychotropic medications, such as Atypical Antipsychotics (AAs), Selective Serotonin Reuptake Inhibitors (SSRIs), and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs), and congenital anomalies in newborns. The analysis uses data from the Food and Drug Administration Adverse Event Reporting System (FAERS).
Methods: Spontaneously reported cases of congenital anomalies in newborns (under 28 days old) were extracted from the FAERS database, covering January 2004 to June 2023.
Nervenarzt
December 2024
Klinik für Psychiatrie und Psychotherapie, Universität zu Köln, Köln, Deutschland.
Background: Antidepressant pharmacotherapy often does not result in the desired effect despite adequate duration and dose. Better evidence on second-step strategies is needed.
Objective: Overview of the current evidence for various pharmacological second-step strategies after nonresponse to antidepressant monotherapy.
Clin Neurol Neurosurg
December 2024
Department of Pharmacy, Massachusetts General Hospital, Boston, MA, United States.
Background: Hyponatremia is common following subarachnoid hemorrhage (SAH) and is associated with vasospasm and delayed cerebral ischemia (DCI). Risk factors for post-SAH hyponatremia are poorly defined; however, selective serotonin reuptake inhibitors (SSRIs) and selective norepinephrine reuptake inhibitors (SNRIs) are associated with hyponatremia in non-SAH populations. This study assessed whether pre-admission SSRIs/SNRIs were associated with hyponatremia after SAH.
View Article and Find Full Text PDFEurasian J Med
October 2024
Department of Psychiatry, Recep Tayyip Erdoğan University Faculty of Medicine, Rize, Türkiye.
Pregnancy is a period in a woman's life during which she experiences physiological, psychological, and social changes. These changes can lead to various mental illnesses, including postpartum depression (PPD), which is common during the perinatal period. Postpartum depression is a significant cause of morbidity and mortality for both the mother and baby.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!